Researchers at the University of Waterloo have developed a new gene therapy platform using the M13 bacteriophage, a simple and customizable single-stranded DNA virus, to deliver therapeutic genes to human cells.

This innovative approach leverages the structural simplicity of the M13 phage, allowing for precise customization to target various diseases, including inherited disorders and cancers.

The research underscores the potential of genetic medicine as a powerful, curative tool for global health challenges, with ongoing efforts to apply this system to neuronal damage repair.

Published in 'Molecular Therapy Nucleic Acids' in 2025, the study highlights how this platform could revolutionize personalized treatments and make gene therapy more accessible.

Led by Dr. Roderick Slavcev, the research team believes this platform could fill the gap in accessible treatments for many genetic conditions.

The technology is being explored for a broad range of applications, including replacing damaged neurons in stroke or Alzheimer’s disease, as well as treating inherited diseases, cancer, and neurological disorders.

This phage-based gene therapy method is potentially more cost-effective and efficient than current viral and non-viral therapies, with the possibility of reducing treatment costs to as low as one-millionth of existing options.

Unlike current gene therapies, which can be costly and trigger immune reactions, this approach aims to overcome these limitations, offering a safer and more affordable alternative.